Valye reports for unlimited access

Galaxy Enterprises Inc. is a development stage company incorporated in Wyoming in 2021, intending to offer real estate management and consulting services primarily in the Las Vegas, Nevada area. The company plans to provide property management services including tenant screening, lease administration, rent collection, maintenance oversight, and financial reporting for residential, commercial, and industrial properties. Additionally, it aims to offer property consulting services such as market analysis, valuation, feasibility studies, site selection, strategic planning, and capital management advice. Revenue generation is planned through monthly fees based on rental income percentages for management services and hourly or negotiated fees for consulting. The company has not yet commenced significant operations and has incurred cumulative losses since inception. It currently operates with a sole officer and director and plans to expand staff as business develops. Marketing efforts will focus on commercial and multi-unit residential properties leveraging the president's experience and local business relationships, with an emphasis on internet and social media advertising. The company faces a highly fragmented and competitive market with established national and local competitors. It is subject to Nevada state licensing requirements for real estate brokers and property managers. As of October 31, 2025, the company has limited cash and current assets relative to liabilities, resulting in liquidity constraints and substantial doubt about its ability to continue as a going concern [S1][S2].

Creative Media & Community Trust Corporation (CMCT) is a publicly traded real estate investment trust (REIT) headquartered in Maryland. The company primarily acquires, develops, owns, and operates premier multifamily properties and Class A and creative office real estate assets in select U.S. communities characterized by high barriers to entry, population growth, and redevelopment activity. CMCT leverages the expertise of CIM Group for asset acquisition, development, and management. As of December 31, 2025, CMCT's portfolio included 27 fee-simple properties and five properties held through unconsolidated joint ventures, comprising office, multifamily, hotel, and development sites. The office portfolio totaled approximately 1.3 million rentable square feet with 74.8% occupancy, while the multifamily portfolio included 801 units with 85.3% occupancy. The company also owns the Sheraton Grand Hotel in Sacramento, CA. CMCT completed a $21.2 million rooms renovation at the hotel and began lobby renovations in 2025. The company sold its lending division in January 2026. CMCT's common stock trades on Nasdaq under the ticker symbol CMCT.

ACRES Commercial Realty Corp. is a commercial real estate company engaged primarily in commercial mortgage loans and related real estate activities. The company securitizes assets through instruments such as collateralized loan obligations (CLOs) and participates in joint ventures involving construction and bridge loans. It maintains a governance framework for cybersecurity risk management involving third-party consultants and Board oversight. Financial disclosures for the fiscal year ended December 31, 2025, show revenues near $80 million and net income close to $28 million, with a modest earnings per share figure. Insider transactions have occurred during 2025, reflecting some insider liquidity.

Tenax Therapeutics, Inc. is a development-stage pharmaceutical company specializing in novel cardiopulmonary therapies. Its lead product candidate is oral levosimendan (TNX-103), targeting pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), a condition with no currently approved therapies. The company is conducting two Phase 3 clinical trials, LEVEL and LEVEL-2, to evaluate levosimendan's efficacy and safety. Tenax also holds rights to imatinib for pulmonary arterial hypertension but has deprioritized its development. The company leverages a clinician-driven approach and licenses its key product from Orion Corporation. Manufacturing is outsourced to third parties. Financially, Tenax reported a net loss of $52.6 million for 2025 and maintains strong liquidity with $97.6 million in cash and equivalents as of year-end. The company has raised capital through private placements to fund ongoing clinical programs. Risks include clinical trial outcomes, regulatory approval, market acceptance, competition, and capital requirements.

Optical Cable Corporation, founded in 1983 and headquartered in Roanoke, Virginia, designs, manufactures, and sells fiber optic and copper cabling and connectivity solutions. Its product portfolio spans fiber optic cables, copper and hybrid cabling, connectors, assemblies, and related infrastructure components tailored for enterprise, data center, harsh environment, military, and specialty applications. The company operates three primary manufacturing facilities, each with relevant quality and military certifications. OCC markets its products through its subsidiary Applied Optical Systems, Inc., and has recently expanded its offerings through a strategic collaboration with Lightera, LLC, enhancing its data center and enterprise sector solutions.

Canterbury Park Holding Corp is a publicly traded company engaged in the gaming and entertainment industry, with operations spanning horse racing, casino gaming, food and beverage services, and property development. The company’s financial disclosures indicate a diversified business model with multiple operating segments. As of December 31, 2025, the company held total assets of approximately $114.4 million and liabilities of about $31.3 million, resulting in stockholders' equity near $83.1 million. The company maintains a strong liquidity position with cash, short-term investments, and favorable liquidity ratios. Recent financial results have shown variability, with some quarters experiencing declines in earnings and revenues, particularly in the casino segment. The company also pays regular quarterly dividends and manages stock-based compensation expenses.

Legend Biotech Corp operates as a global biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of cell therapies targeting oncology and other indications. Its lead product, CARVYKTI (cilta-cel), is a CAR-T therapy approved by the FDA for treatment of relapsed or refractory multiple myeloma. The company collaborates with Janssen under a profit-sharing and license agreement, sharing development, manufacturing, and commercialization activities. Revenue streams include collaboration revenue from Janssen, license revenue from Novartis and other agreements, and milestone payments contingent on clinical and commercial achievements. The company has incurred significant operating losses since inception but maintains liquidity through cash reserves, equity offerings, and milestone payments. It invests in research and development, manufacturing infrastructure, and commercial capabilities across the United States, Europe, and China.

Cullinan Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies primarily for autoimmune diseases and oncology. Its pipeline includes product candidates such as CLN-978 and CLN-049, with ongoing Phase 1 clinical trials and regulatory designations. The company collaborates with Taiho Pharmaceutical on oncology drug development. Cullinan faces typical clinical-stage risks including patient enrollment challenges and competition in clinical trials. It maintains strong liquidity and has transitioned to smaller reporting company status, allowing for reduced disclosure requirements.

BioNTech SE, headquartered in Mainz, Germany, is a biotechnology company focused on developing immunotherapies to improve global health. Founded in 2008 by scientists and physicians, the company combines fundamental research with operational excellence. BioNTech's product portfolio includes COVID-19 vaccines and oncology candidates, with a notable global collaboration with Bristol-Myers Squibb to co-develop and commercialize the bispecific antibody pumitamig. The company operates as a single reporting segment and has a centralized governance structure for cybersecurity and data privacy. Financially, BioNTech reported €2.87 billion in revenues for 2025, driven by vaccine sales and licensing revenues, but incurred a net loss of €1.14 billion. The company holds substantial liquidity and continues to invest in research and development, with a focus on late-stage clinical trials and pipeline prioritization.

Hewlett Packard Enterprise Co (HPE) develops and delivers technology solutions that enable customers to capture, analyze, and act on data seamlessly from edge to cloud environments. The company serves a diverse customer base ranging from small and medium businesses to large enterprises and government entities. HPE's strategic focus centers on leveraging megatrends in networking, cloud computing, data, and artificial intelligence (AI) to provide integrated, AI-native networking solutions and hybrid multi-cloud experiences. The acquisition of Juniper Networks in 2025 expanded HPE's networking technology stack, enabling secure, AI-driven networking offerings. HPE GreenLake cloud platform offers a hybrid cloud experience with pay-per-use consumption and automated scalability. The company operates through three main segments: Cloud & AI (which includes server, hybrid cloud, and financial services), Networking, and Corporate Investments and Other. HPE's financial services support customer adoption of AI and IT lifecycle services. The company maintains a global manufacturing footprint and faces risks including supply chain disruptions, competitive pressures, and cybersecurity threats.

ImageneBio, Inc. is a Nasdaq-listed biopharmaceutical company formed through the merger of Ikena Oncology and Inmagene Biopharmaceuticals. The company focuses on advancing clinical development of its product candidates, including IMG-007. The merger involved a reverse stock split and was supported by major proxy advisory firms. Leadership changes include the appointment of Kristin Yarema, Ph.D. as CEO. The company reported a net loss for fiscal 2025 but holds substantial cash and short-term investments, indicating a strong liquidity position.

Inspired Entertainment, Inc. operates as a global gaming technology company supplying content, platforms, and services to licensed online and land-based lottery, betting, and gaming operators worldwide. The company offers end-to-end digital gaming solutions through proprietary networks and third-party platforms, serving a diverse customer base including major operators such as William Hill, DraftKings, and Entain. Its business is organized into four segments: Gaming, Virtual Sports, Interactive, and Leisure. The Gaming segment provides gaming terminals and software to land-based venues, with approximately 35,000 terminals installed as of 2025. The Virtual Sports segment offers computer-rendered sports simulations for wagering, available in over 25,000 retail venues and online platforms globally. The Interactive segment develops online gaming content distributed across over 500 websites in regulated markets. The Leisure segment supplies gaming terminals to pubs, bingo halls, and adult gaming centers. The company generates most revenue from recurring, participation-based contracts with long-term durations. Geographically, the UK accounts for the majority of revenue, with significant operations in Greece, North America, and other regions. Inspired holds multiple gaming licenses across jurisdictions and employs approximately 1,020 people. The company reported total revenue of $304.1 million and Adjusted EBITDA of $111.4 million for 2025, with a net loss of $17 million. Liquidity metrics indicate a current ratio of 2.23 and cash ratio of 0.67 as of year-end 2025.

Exagen Inc. focuses on developing and commercializing diagnostic testing products under the AVISE® brand for autoimmune and rheumatic diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's flagship product, AVISE® CTD, launched in 2012, aids clinicians in differential diagnosis of connective tissue diseases and related conditions with overlapping symptoms. The company operates a CLIA-certified and CAP-accredited laboratory in Vista, California, performing all tests in-house and reporting results typically within five business days. Exagen markets its products through a specialized sales force trained to interpret test results and engage rheumatologists. Revenue is primarily generated from AVISE® CTD tests, which accounted for the majority of revenue in recent periods. The company has enhanced its product offerings with new biomarker assays, including PAD4, SLE, and RA disease activity markers, and is actively engaged in research and development to expand its testing portfolio. Exagen also pursues partnerships with pharmaceutical companies and academic institutions to leverage its testing products and data. The company has undergone an operational turnaround since late 2022, achieving revenue growth, gross margin expansion, and reduced operating expenses. Financially, as of December 31, 2025, Exagen reported a net loss and maintains liquidity supported by cash reserves and a term loan facility with covenants. The company faces risks related to reimbursement coverage, payor concentration, and the timing and costs of research and development activities.

Priority Technology Holdings, Inc. is a fintech company specializing in payments and banking solutions through its integrated commerce engine. The company operates three main segments: Merchant Solutions, which offers full-service acquiring and payment solutions for B2C transactions; Payables, providing accounts payable automation and working capital access; and Treasury Solutions, delivering embedded finance and Banking-as-a-Service (BaaS) products. Priority serves a diverse customer base across multiple industries and maintains a large reseller network of approximately 1,100 partners. The company’s proprietary technology platform supports a wide range of payment types and is designed for scalability and operational efficiency. Priority holds extensive money transmission licenses and partners with several sponsor banks to facilitate payment processing and banking services. The company’s growth strategy includes organic expansion, technology deployment, and strategic acquisitions such as the 2023 acquisition of Plastiq Inc. Priority is ranked as the 5th largest non-bank merchant acquirer in the U.S. by volume. The company operates in a competitive and highly regulated industry, emphasizing innovation, customer service, and compliance.

SS Innovations International, Inc. develops and markets the SSi Mantra surgical robotic system, an affordable next-generation platform designed to perform a wide range of soft-tissue, robotically assisted surgeries. The company operates primarily in India, with 87% of revenue generated domestically in 2025 and 13% internationally. The business model includes system sales, instruments, accessories, and post-sale warranty and maintenance services. Revenue recognition follows ASC 606 principles, with system sales recognized upon delivery and deferred payment arrangements accounted for at present value. The company also offers pay-per-use leasing arrangements with variable payments based on surgical activity. SS Innovations completed its uplisting to NASDAQ in April 2025 and operates as a single reportable segment. The company has achieved operational milestones including over 100 system installations worldwide and pioneering robotic telesurgery procedures.

Prelude Therapeutics Inc is a biotechnology company engaged in the research, preclinical, and clinical development of novel product candidates primarily in oncology and related therapeutic areas. The company has not yet commercialized any products and does not generate revenue. Its pipeline includes early-stage candidates such as PRT12396, for which it received FDA clearance to initiate a Phase I clinical trial in early 2026. Prelude has entered into strategic agreements, including an Exclusive Option Agreement with Incyte Corporation for its mutative selective JAK2V617F inhibitor program, which includes upfront payments and potential milestone and royalty revenues. The company relies on third-party collaborators for clinical trials and manufacturing. As of December 31, 2025, Prelude held approximately $103.2 million in cash and marketable securities, supporting its operations for at least the next twelve months. The company continues to invest in research and development while managing risks inherent to clinical-stage biotechnology firms.

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative therapies for cancer and rare diseases. Its pipeline includes TARA-002, an investigational cell therapy for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral support. The company has no approved products and has not generated revenues from product sales. It finances its operations through equity offerings and relies on third-party contract manufacturers for drug substance and product supply. Protara reported a net loss of $57.4 million for the year ended December 31, 2025, with research and development expenses increasing due to clinical trial activities. The company maintains strong liquidity with nearly $198 million in cash, cash equivalents, and marketable securities as of year-end 2025. Recent milestones include dosing the first patient in a Phase 3 trial and multiple analyst coverage initiations with positive recommendations.

AerSale Corp operates in the aviation aftermarket industry, providing integrated services including sales, leasing, maintenance, repair and overhaul (MRO), and used serviceable material (USM) parts sales for aircraft and engines. The company targets mid-life aircraft owners and operators, offering a comprehensive suite of products and services that span from whole aircraft and engine leasing to component-level MRO and aftermarket parts. AerSale's business model leverages its FAA unlimited repair station ratings, proprietary Engineered Solutions, and extensive market intelligence to deliver cost-effective alternatives to OEM products and services. The company serves a global customer base of over 1,000 clients, including passenger and cargo airlines, governmental agencies, OEMs, and MRO providers. Growth strategies focus on expanding MRO capabilities, increasing government sector presence, and developing new proprietary solutions. AerSale has a history of strategic acquisitions to broaden its capabilities and geographic footprint. The company reported $335.3 million in revenue and $8.575 million in net income for the fiscal year ended December 31, 2025, with a strong liquidity position reflected in a current ratio of 3.71 [S1].

Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies, including RAP-219, for neurological disorders. The company has disclosed significant financial resources as of the end of 2025, including cash, short-term investments, and a strong liquidity position. It has engaged in a public offering to raise additional capital to fund ongoing clinical trials and research and development activities. Recent business developments include a collaboration with Tenacia for commercialization of RAP-219 in Greater China. The company has attracted attention from multiple financial analysts and institutional investors, with several buy and overweight recommendations reported in recent months.

Q32 Bio Inc. operates as a clinical-stage biotechnology company engaged in the research and development of novel biologic therapies. Its lead product candidate, bempikibart, is in clinical trials for the treatment of alopecia areata and has received Fast Track designation from the FDA. The company also developed ADX-097, a complement inhibitor, which it sold to Akebia Therapeutics in late 2025, receiving upfront payments, milestone payments, and potential royalties. Q32 Bio has no products approved for commercial sale and has historically incurred operating losses. The company maintains strong liquidity with cash and equivalents of approximately $48 million as of the end of 2025. It relies on third-party contract research and manufacturing organizations, including foreign providers, to support its clinical development and manufacturing activities. The company faces competition from larger biopharmaceutical firms and must navigate regulatory, clinical, and operational risks typical of early-stage biotech companies.

Custom Truck One Source, Inc. operates as a provider of truck parts and services, with publicly disclosed financial results indicating annual revenues near $1.94 billion for fiscal year 2025. The company reported a net loss for the year and maintains liquidity with a current ratio above 1.3. It regularly files detailed financial reports with the SEC and communicates updates through investor presentations. Recent news coverage focuses on quarterly earnings performance and market positioning relative to industry peers.

TWFG, Inc. is an independent distribution platform for personal and commercial insurance in the United States, founded in 2001. The company operates a unique agency model that supports over 3,000 agencies, including exclusive TWFG branded Branches and non-branded MGA Agencies, across multiple states. TWFG offers a comprehensive suite of insurance products, including personal lines such as auto and home, and commercial lines such as general liability and workers' compensation. The company provides agents with proprietary technology, training, marketing support, and access to over 300 insurance carriers. TWFG's revenue primarily derives from commissions on insurance premiums, with an average commission rate of approximately 12.8% in 2025. The business model includes a revenue and work sharing structure that incentivizes agents to grow their books of business and maintain client relationships. TWFG has demonstrated consistent growth, with 2025 revenues of $248.5 million and net income of $41.2 million, supported by organic growth and acquisitions. The company maintains strong liquidity and capital resources, with cash and equivalents of $155.9 million as of year-end 2025.

Bullish operates a digital asset exchange platform and related services, including liquidity services, subscription and data services, and CoinDesk-related revenue streams. The company is incorporated in the Cayman Islands and listed on the NYSE as a foreign private issuer. Bullish reported fiscal year 2025 revenue of approximately $244.8 billion USD, primarily from digital asset sales, but also includes other revenues such as subscription fees and promotional income. The company reported a net loss of approximately $785 million USD for 2025, with a negative EPS of $5.99. Bullish holds digital assets partly classified as indefinite-life intangible assets, revalued through other comprehensive income, reflecting a strategic shift to long-term investment. The company had cash and cash equivalents of about $87.9 million USD and a strong current ratio of 29.28 as of December 31, 2025. Bullish employs over 400 personnel globally, primarily in technology, security, and operations. The company maintains effective disclosure controls and a comprehensive cybersecurity risk management program. Corporate governance follows Cayman Islands practices with an independent audit committee. Executive compensation includes base salary, bonuses, and equity awards under an Omnibus Incentive Plan. Recent news includes earnings call transcripts and analyst recommendations maintaining buy or neutral ratings, alongside notable option activity and stock price movements in early 2026 [S1][N3][N6][N1].

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on developing innovative therapies in oncology and obesity. Its pipeline includes CRB-701, a next-generation antibody drug conjugate targeting Nectin-4 on cancer cells, and CRB-913, a peripherally restricted CB1 receptor inverse agonist for obesity treatment. CRB-701 is in Phase 1/2 clinical trials in the U.S. and Europe, with dose expansion ongoing, and a Phase 3 trial in China conducted by CSPC. The drug has received FDA fast track designations for certain cancer indications. CRB-913 completed a Phase 1a study demonstrating safety and early weight loss signals, with a Phase 1b dose-ranging study initiated in late 2025. The company has deprioritized CRB-601, an anti-integrin monoclonal antibody program. Corbus does not own manufacturing facilities and relies on third-party contract manufacturers and licensing partners. Financially, the company reported a net loss of $78.5 million for 2025, with cash and equivalents of $28.5 million and a strong current ratio of 8.07 as of December 31, 2025. Research and development expenses increased significantly in 2025. The company holds intellectual property protections for its drug candidates with patent expirations extending into the 2040s. Recent news highlights include positive clinical data releases and analyst recommendations maintaining favorable views on the company.

Repay Holdings Corp operates as a holding company with its main asset being its ownership interest in Hawk Parent, which conducts the operating business. The company does not generate independent revenue or cash flow but relies on distributions from Hawk Parent to meet its financial obligations, including taxes, debt payments, and potential dividends. The business is subject to extensive regulatory and contractual requirements to maintain the confidentiality and security of consumer information. It maintains a structured cybersecurity program overseen by a dedicated Chief Information Security Officer and a Security and Privacy Steering Committee. The company has significant indebtedness, including revolving credit facilities and convertible senior notes, with restrictive covenants that limit financial and operational flexibility. Liquidity as of December 31, 2025, shows current assets below current liabilities, with a current ratio below 1. The company reported a substantial net loss and negative earnings per share for the fiscal year 2025. The stock has historically experienced substantial price volatility. Recent news reports indicate the company lagged in Q4 earnings results.

Septerna, Inc. operates as a clinical-stage biopharmaceutical company focused on developing novel therapeutics using its proprietary Native Complex Platform® technology. The company is advancing product candidates through clinical trials, including SEP-631, which has shown positive Phase 1 data and is planned for Phase 2 trials targeting chronic spontaneous urticaria. Septerna's financial disclosures indicate ongoing net losses typical of development-stage biopharma firms, supported by substantial cash and short-term investments providing liquidity. The company is publicly traded on the Nasdaq Global Market under the ticker SEPN.

Kronos Worldwide Inc operates primarily in the titanium dioxide (TiO2) manufacturing segment, with a single reportable operating segment. The company’s operations span multiple geographies including the United States, Germany, Canada, Norway, Belgium, and other regions. Revenue is generated from net sales both by point of origin and point of destination, with total net sales for the nine months ended September 30, 2025 of approximately $1.44 billion. The company evaluates segment performance based on net income and segment profit before income tax and certain corporate items. Kronos maintains significant assets and liabilities, including long-term debt and pension obligations, and manages liquidity with a current ratio of 2.7 as of December 31, 2025.

MacroGenics Inc. develops innovative antibody-based therapeutics primarily for cancer treatment, leveraging proprietary technology platforms including antibody-drug conjugates and multi-specific antibodies (DART and TRIDENT). The company has three FDA-approved products for which it retains economic rights, and it actively advances multiple clinical and preclinical candidates. Strategic collaborations with Incyte and Gilead provide substantial non-dilutive funding and development support. The company operates a commercial-scale manufacturing facility in Maryland, which also offers contract services to collaborators. MacroGenics began generating product sales revenue in 2021 and continues to invest in research and development while managing financial resources through collaborations and securities offerings.

Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the development of GeneTAC® molecules, a novel class of small-molecule gene targeted chimera therapeutics designed to modulate gene expression in diseases caused by inherited nucleotide repeat expansions. The company’s platform targets diseases such as Friedreich ataxia, fragile X syndrome, myotonic dystrophy type-1, Fuchs endothelial corneal dystrophy, and Huntington’s disease. Its lead candidate, DT-216P2, is in Phase 1/2 clinical trials for Friedreich ataxia, with other candidates in various stages of clinical and preclinical development. The company has incurred net losses since inception and has not generated revenue from product sales. It funds operations primarily through equity offerings and grants, maintaining a strong liquidity position as of the end of 2025 [S1].

Eagle Bancorp Inc operates primarily as a commercial bank through its subsidiary EagleBank, offering banking services via physical branches and digital platforms. It has three subsidiaries focused on real estate owned through foreclosure, insurance referral fee income, and municipal lending. The company consolidates its financials under US GAAP and reports as a single operating segment. It manages credit risk through a detailed allowance for credit losses model incorporating historical data and economic forecasts. Interest rate risk is managed via a macro hedging program using interest rate swaps. The company’s balance sheet includes a diversified deposit base, investment securities, loans, and borrowings including senior notes. Recent financial results show net losses and elevated credit loss provisions, with ongoing operational expenses including salaries, marketing, and FDIC insurance. The company discontinued its sweep account product in late 2025.

Financial Institutions, Inc. is a financial holding company with a long history dating back to 1817, operating primarily through Five Star Bank and Courier Capital LLC. Five Star Bank offers a full range of banking services including deposits and loans across Western and Central New York, with additional loan production offices in Maryland and Syracuse, NY. Courier Capital provides investment management and retirement plan services with $3.60 billion in assets under management. The company’s strategy centers on community banking with personalized service, combining physical branches and digital channels to meet customer needs. It focuses on organic growth within existing markets and evaluates acquisition opportunities that align with its core competencies. The company operates in a competitive regional market with a diversified revenue base and a strong emphasis on employee development and inclusivity.

Box Inc offers a cloud-based Intelligent Content Management (ICM) platform that enables organizations to securely manage unstructured data throughout its lifecycle. The platform supports content creation, sharing, editing, approval, signing, classification, and retention with enterprise-grade security and compliance features. Box's SaaS model facilitates secure collaboration both internally and externally, with integrations to over 1,500 business applications and support for numerous file formats and devices. The company targets primarily large enterprises through a combination of high-touch sales, self-service online sales, and channel partners. Box also provides developer tools and APIs for custom application development and extends AI capabilities through its Box AI platform. As of January 31, 2026, Box served over 100,000 paying organizations worldwide and offers its solution in 25 languages. The company reported net income of $115.38 million and maintains a current ratio of 1.11 as of the fiscal year ended January 31, 2026 [S1].

Castellum, Inc. operates as a technology services, solutions, and products company focused on cybersecurity, IT, electronic warfare, information warfare, system modernization, and information operations. Its services include intelligence analysis, software development and engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and model based systems engineering. The company primarily serves U.S. government agencies across defense, intelligence, federal civilian, state, and local markets, as well as commercial clients. Castellum’s market segments include Digital Solutions, C4ISR, Cyber & Space, Engineering Services, IT Services, and Mission Support. The company’s contracts are mostly annual with options to renew and include various contract types such as firm fixed price, cost plus fixed fee, and time and materials. It has completed seven acquisitions since 2019 and pursues growth through both organic means and strategic acquisitions. The company maintains a qualified opportunity pipeline valued at approximately $817 million as of December 31, 2025. Key contracts include those with Naval Air Systems Command, Special Missions Management of On-Site Services, and Naval Sea Systems Command. As of December 31, 2025, Castellum reported revenue of about $52.9 million and a net loss of $2.4 million, with a current ratio of 4.4 indicating strong liquidity. The company employs 244 personnel, most holding security clearances and STEM-related degrees. Risks include dependence on government budgets, competition, and challenges in maintaining security clearances.

ALX Oncology Holdings Inc is a clinical-stage biopharmaceutical company incorporated in 2015, developing immuno-oncology therapies targeting cancer. Its lead product candidates, evorpacept (ALX 148) and ALX2004, are in early-stage clinical trials, with no products yet approved for commercial sale. The company has not generated revenue from product sales, licenses, or collaborations. ALX Oncology's operations focus on research and development, clinical trials, and capital raising activities. It relies on third-party manufacturers for clinical supplies and has no internal sales or marketing infrastructure. The company has incurred significant net losses since inception and requires substantial additional capital to continue operations and advance its clinical programs. It maintains a loan agreement with lenders providing potential funding subject to covenants and lender discretion. The company faces risks related to clinical development, regulatory approval, capital requirements, competition, and operational execution.

3D Systems Corporation operates through subsidiaries worldwide, offering comprehensive additive manufacturing solutions that include hardware, proprietary materials, software, and services. The company targets two main verticals: Healthcare Solutions, encompassing medical devices, dental, personalized health services, and regenerative medicine; and Industrial Solutions, focusing on aerospace, defense, transportation, and general manufacturing. Its business strategy emphasizes accelerating additive manufacturing adoption by integrating hardware, materials, software, and application engineering to enable customers to optimize designs and scale production. The company maintains manufacturing facilities in the U.S. and Europe and supports customers globally through direct sales, channel partners, and distributors. 3D Systems invests in R&D, holds a significant patent portfolio, and provides advanced manufacturing services and training to support customer adoption of additive manufacturing technologies.

Tiptree Inc. operates as a holding company that invests in small and middle market companies, with a focus on insurance and credit-related financial sectors. The company seeks controlling interests in businesses with long-term growth potential, stable cash flows, scalable models, and strong management. Tiptree emphasizes disciplined underwriting and a patient capital approach to generate consistent earnings and cash flow. The company has recently entered into agreements to sell its insurance subsidiary Fortegra and mortgage operation Reliance, which are now classified as held for sale and discontinued operations. Post-sale, Tiptree's operations will focus on its retained business with fewer assets and increased exposure to operational risks. The company maintains a lean corporate staff responsible for strategy, capital allocation, and compliance. Tiptree is subject to regulatory constraints including the Investment Company Act of 1940 and faces cybersecurity and data privacy risks inherent in its operations.